HRT vs Non-Hormonal Menopause Treatment: Evidence-Based Comparison

Choosing between HRT vs non-hormonal menopause treatment is one of the most consequential decisions women face in midlife — and the evidence base shifted meaningfully between 2022 and 2024. Systemic hormone therapy remains the most effective option for moderate-to-severe vasomotor symptoms, but a newer class of non-hormonal drugs (NK3 receptor antagonists like fezolinetant), refined SSRI/SNRI dosing, and stronger behavioral data have expanded what clinicians can offer when HRT is contraindicated or undesired. This editorial guide compares both pathways across efficacy, safety, cost, and access — without prescribing a single right answer.

Key facts at a glance

• Systemic HRT cuts hot-flash frequency by approximately 75% in pooled RCT data¹.
• Fezolinetant (Veozah), the first FDA-approved NK3 receptor antagonist, reduces moderate-to-severe hot flashes by ~60% at 12 weeks³.
• NAMS 2022 affirms HRT as first-line for symptomatic women under 60 or within 10 years of menopause when not contraindicated¹.
• Non-hormonal options are first-line when HRT is contraindicated, per NAMS 2023 and ACOG 2024²,⁵.

HRT vs non-hormonal menopause treatment: direct answer

For most symptomatic women under 60 or within 10 years of their final menstrual period, systemic estrogen therapy (with progestogen if a uterus is present) provides the largest reduction in vasomotor symptoms — roughly 75% reduction versus ~25–30% for placebo in Cochrane-pooled trials⁴. The 2022 NAMS Position Statement reaffirms HRT as first-line for healthy symptomatic women in this window, with a favorable risk-benefit profile¹. However, "first-line" does not mean "only line." The 2023 NAMS Nonhormonal Position Statement and the 2024 ACOG Clinical Practice Guideline both recognize that an expanding non-hormonal toolkit — fezolinetant, paroxetine 7.5 mg, SNRIs (venlafaxine, desvenlafaxine), gabapentin, oxybutynin, and cognitive behavioral therapy (CBT) — can deliver clinically meaningful relief, especially when HRT is contraindicated or declined²,⁵. The right choice depends on symptom severity, personal and family history, age, time since menopause, and patient preference — a conversation that belongs with a clinician.

How HRT works — and what the data show

Systemic HRT replaces declining endogenous estrogen (and, when needed, progesterone to protect the endometrium). It directly addresses the hypothalamic thermoregulatory dysfunction that drives hot flashes, plus genitourinary atrophy, sleep disruption, and bone loss.

Efficacy numbers

A Cochrane meta-analysis of 24 trials (n=3,329) found oral estrogen reduced hot-flash frequency by 75% versus 51% reduction for placebo — a 24-percentage-point absolute benefit⁴. Transdermal estradiol patches (typically 0.025–0.1 mg/day) deliver comparable symptom relief with potentially lower VTE risk than oral routes per NAMS¹. Vaginal estrogen, at doses 10–50× lower than systemic, treats genitourinary syndrome of menopause without meaningful systemic absorption.

Safety profile

The Women's Health Initiative long-term follow-up (n=27,347, 18-year mortality data) found no increase in all-cause mortality with either estrogen-alone or estrogen-plus-progestin regimens versus placebo⁸. Risks that remain clinically relevant: a small absolute increase in breast cancer with combined therapy after ~5 years (≈8 additional cases per 10,000 women-years), VTE (more pronounced with oral than transdermal), and stroke in older initiators¹. These risks shaped the NAMS "timing hypothesis" — initiation under 60 or within 10 years of menopause carries the most favorable risk profile¹.

Non-hormonal menopause treatment options

The non-hormonal landscape expanded significantly with fezolinetant's 2023 FDA approval, and the 2023 NAMS and 2024 ACOG statements now provide structured guidance².

Fezolinetant (Veozah)

A neurokinin-3 (NK3) receptor antagonist targeting the KNDy neurons in the hypothalamus that drive hot flashes. In the SKYLIGHT 1 phase 3 trial (n=527), fezolinetant 45 mg reduced moderate-to-severe vasomotor symptoms by ~60% at week 12 versus ~45% for placebo³. FDA labeling requires liver function monitoring at baseline, months 3, 6, and 9 due to transaminase elevations observed in trials⁷.

Low-dose paroxetine 7.5 mg (Brisdelle)

The only FDA-approved SSRI specifically for menopausal vasomotor symptoms. Two pivotal RCTs showed a 33–65% reduction in weekly hot-flash frequency versus placebo, with effects emerging by week 4⁶. Notably, paroxetine 7.5 mg interacts with tamoxifen — a clinically important consideration for breast cancer survivors.

SNRIs, gabapentin, oxybutynin, CBT

Venlafaxine 75 mg and desvenlafaxine 100 mg show ~50–60% hot-flash reduction. Gabapentin 900 mg/day shows ~45% reduction with sleep benefit. Oxybutynin 2.5–5 mg twice daily shows ~70% reduction but carries anticholinergic concerns in older women. CBT and clinical hypnosis are recommended non-pharmacologic options per NAMS 2023².

Comparing treatment pathways in practice

In editorial third-person framing, common clinical approaches include the following — none of which constitute a recommendation; selection is individualized with a clinician.

For a healthy 52-year-old within 8 years of menopause with moderate hot flashes and no contraindications: clinicians often discuss transdermal estradiol (0.05 mg/day patch) plus oral micronized progesterone 100 mg nightly if a uterus is present.

For a 54-year-old breast cancer survivor on tamoxifen: HRT is generally contraindicated. Non-hormonal options like fezolinetant 45 mg daily (with liver monitoring), venlafaxine 75 mg, gabapentin 900 mg/day, or oxybutynin may be discussed — paroxetine is typically avoided due to tamoxifen interaction².

For a 60-year-old more than 10 years post-menopause: the NAMS timing hypothesis suggests initiating systemic HRT here carries higher cardiovascular and stroke risk; non-hormonal options or vaginal estrogen for localized symptoms are often discussed first¹.

For a patient preferring non-pharmacologic care: CBT delivered over 4–8 sessions has RCT evidence for hot-flash bother reduction and sleep improvement².

Telehealth provider options for HRT and non-hormonal care

Several telehealth providers offer menopause care covering both HRT and non-hormonal pathways, with meaningfully different access models. Midi Health accepts most commercial insurance plans and Medicare in many states, with NAMS-certified clinicians who prescribe across the full menopause toolkit including HRT, fezolinetant, and SSRIs. Winona operates as a cash-pay, async-first model focused on bioidentical HRT prescribing, with monthly subscription pricing that bundles consultation and pharmacy. Alloy Women's Health offers physician-led HRT prescribing on a cash-pay basis with optional non-hormonal add-ons. Evernow provides asynchronous menopause care with both hormonal and non-hormonal protocols and bundled labs.

Differentiators matter more than rankings: insurance acceptance, synchronous vs asynchronous visits, NAMS certification, in-house pharmacy, and whether labs are included or billed separately all shape total cost and clinical fit. Some brand mentions link to our editorial reviews.

Safety, contraindications, and red flags

Both pathways have specific safety guardrails grounded in NAMS, ACOG, and FDA labeling.

HRT is generally contraindicated in women with: history of breast cancer or estrogen-sensitive malignancy, unexplained vaginal bleeding, active or recent VTE/PE, active liver disease, known coronary artery disease, or recent stroke or TIA¹,⁵. Transdermal routes may be preferred over oral in women with elevated VTE risk per NAMS¹.

Non-hormonal cautions include: fezolinetant requires baseline liver function and follow-up monitoring at months 3, 6, and 9 — discontinue for ALT/AST elevations above thresholds in the FDA label⁷. SSRIs/SNRIs require taper to avoid discontinuation syndrome and interact with tamoxifen (especially paroxetine and fluoxetine). Gabapentin can cause sedation and falls in older adults. Oxybutynin's anticholinergic burden is a concern for women at risk of cognitive decline².

Red flags warranting urgent clinical evaluation include: new unilateral leg swelling or chest pain (possible VTE/PE), sudden severe headache or unilateral weakness (possible stroke), unexplained postmenopausal bleeding (possible endometrial pathology), new breast lump, or yellowing of skin/eyes (possible liver injury on fezolinetant).

Cost and insurance considerations

Cost gaps between HRT and non-hormonal pathways are substantial and often drive real-world choice.

Generic transdermal estradiol patches typically run $15–$50/month cash, with insurance copays often $0–$20. Oral micronized progesterone runs $20–$60/month generic. Telehealth platform fees range from $25 (Alloy bundled) to $100+/month for synchronous insurance-accepting models like Midi Health, though insurance often covers the visit portion when accepted.

Fezolinetant (Veozah) lists at approximately $550/month without insurance per AWP data; commercial coverage is variable and many plans require step therapy. Low-dose paroxetine 7.5 mg (Brisdelle) lists around $200/month branded; generic paroxetine at higher doses runs under $15/month but is off-label for vasomotor symptoms. Generic gabapentin and venlafaxine are typically under $20/month. CBT may be covered by mental-health benefits — verification with the insurer is recommended.

Insurance variability is the rule, not the exception. Verifying coverage before starting and discussing cash-pay alternatives with a clinician is prudent.

Frequently asked questions

Is HRT or a non-hormonal option more effective for hot flashes? In head-to-head data, systemic estrogen reduces hot-flash frequency by ~75% versus ~60% for fezolinetant and ~33–65% for SSRIs/SNRIs like paroxetine 7.5 mg. HRT remains the most effective for vasomotor symptoms per NAMS 2022, but non-hormonal options are first-line when HRT is contraindicated. Discuss the trade-offs with a clinician.

Who should avoid HRT and use non-hormonal menopause treatment instead? Per ACOG and NAMS, HRT is generally avoided in women with a history of breast cancer, estrogen-sensitive cancer, unexplained vaginal bleeding, active VTE or stroke, active liver disease, or known coronary artery disease. Non-hormonal options like fezolinetant, paroxetine 7.5 mg, gabapentin, or CBT are typical alternatives — selection should be individualized with a clinician.

How much does HRT cost vs non-hormonal menopause treatment? Telehealth HRT subscriptions typically run $25–$100/month plus medication ($10–$50/month generic estradiol). Fezolinetant (Veozah) lists around $550/month without insurance. Generic paroxetine 7.5 mg and gabapentin are often under $20/month. Insurance coverage varies — verify benefits before starting.

Can you combine HRT with non-hormonal options for menopause? Some clinicians layer therapies — for example, vaginal estrogen for genitourinary symptoms plus CBT or an SSRI for mood, or systemic HRT plus gabapentin for sleep. Combination protocols are individualized and require clinician oversight, particularly to monitor drug interactions and total side-effect burden.

How long can someone stay on HRT vs non-hormonal menopause treatment? NAMS 2022 states there is no arbitrary time limit on HRT in appropriately selected patients; risk-benefit should be reassessed annually. Fezolinetant trials run up to 52 weeks. SSRIs and gabapentin are used long-term with periodic review. A clinician should reassess every 12 months.

Does non-hormonal menopause treatment have fewer side effects than HRT? Not necessarily — side-effect profiles differ rather than "fewer vs more." HRT can cause breast tenderness, spotting, and rare VTE/stroke risk. Fezolinetant requires liver enzyme monitoring. SSRIs can cause nausea, sexual dysfunction, and discontinuation syndrome. Gabapentin can cause sedation. A clinician can match profile to tolerability priorities.

Sources

1. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause, 2022;29(7):767-794. https://pubmed.ncbi.nlm.nih.gov/35797481/
2. Nonhormonal Management of Menopause-Associated Vasomotor Symptoms: 2023 Position Statement of The North American Menopause Society. Menopause, 2023;30(6):573-590. https://pubmed.ncbi.nlm.nih.gov/37252752/
3. Lederman S, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3, randomised controlled study. Lancet, 2023;401(10382):1091-1102. https://pubmed.ncbi.nlm.nih.gov/36924778/
4. MacLennan AH, et al. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev, 2004;(4):CD002978. https://pubmed.ncbi.nlm.nih.gov/15495039/
5. ACOG Clinical Practice Guideline No. 6: Management of Menopausal Symptoms. Obstet Gynecol, 2024;143(5):e108-e125. https://pubmed.ncbi.nlm.nih.gov/38626511/
6. Simon JA, et al. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause, 2013;20(10):1027-35. https://pubmed.ncbi.nlm.nih.gov/24045679/
7. U.S. Food & Drug Administration. VEOZAH (fezolinetant) Prescribing Information, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216578s000lbl.pdf
8. Manson JE, et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA, 2017;318(10):927-938. https://pubmed.ncbi.nlm.nih.gov/28898378/

Related brands & guides

• Midi Health — Insurance-accepting NAMS-certified menopause care
• Winona — Cash-pay async bioidentical HRT
• Alloy Women's Health — Physician-led HRT subscription
• Evernow — Async menopause care with hormonal and non-hormonal protocols

Updated May 29, 2026. Reviewed by Dr. Maya Chen, MD, NAMS-CMP. Some brand mentions link to our editorial reviews; this content is informational and does not replace medical advice.